

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> A61K 38/00, 38/04, C07K 14/00	<b>A1</b>	<b>(11) International Publication Number:</b> WO 98/34634 <b>(43) International Publication Date:</b> 13 August 1998 (13.08.98)
<b>(21) International Application Number:</b> PCT/US98/02699 <b>(22) International Filing Date:</b> 6 February 1998 (06.02.98) <b>(30) Priority Data:</b> 08/796,850 6 February 1997 (06.02.97) US <b>(71) Applicant:</b> ENTREMED, INC. [US/US]; Suite 200, 9610 Medical Center Drive, Rockville, MD 20850 (US). <b>(72) Inventors:</b> PAPATHANASSIU, Adonia, E.; Apartment 811, 1220 East-West Highway, Silver Spring, MD 20910 (US). GREEN, Shawn, J.; 9416 Gamba Court, Vienna, VA 22182 (US). <b>(74) Agents:</b> GREENE, Jamie, L. et al.; Jones & Askew, LLP, 37th floor, 191 Peachtree Street, N.E., Atlanta, GA 30303 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> COMPOSITIONS AND METHODS FOR INHIBITING CELLULAR PROLIFERATION		
<b>(57) Abstract</b> <p>Compositions and methods for inhibiting cellular proliferation wherein the composition contains Tissue Factor Pathway Inhibitor (TFPI), a TFPI homolog, or an active fragment thereof. TFPI exhibits potent anti-proliferative activity on human and other animal cells, particularly endothelial cells. More particularly, the TFPI, TFPI homolog, and inhibitory fragment thereof may be combined with a pharmaceutically acceptable excipient or carrier and used to inhibit angiogenesis and angiogenesis-related diseases such as cancer, arthritis, macular degeneration, and diabetic retinopathy.</p>		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

5

1

10

## COMPOSITIONS AND METHODS FOR INHIBITING CELLULAR PROLIFERATION

### FIELD OF THE INVENTION

15

The present invention relates to compositions and methods for the inhibition of cellular proliferation. More particularly, the present invention relates to the use of tissue factor pathway inhibitor and inhibitory fragments thereof to inhibit angiogenesis and angiogenesis-related diseases.

20

### BACKGROUND OF THE INVENTION

25

30

Cellular proliferation is a normal ongoing process in all living organisms and is one that involves numerous factors and signals that are delicately balanced to maintain regular cellular cycles. The general process of cell division is one that consists of two sequential processes: nuclear division (mitosis), and cytoplasmic division (cytokinesis). Because organisms are continually growing and replacing cells, cellular proliferation is a central process that is vital to the normal functioning of almost all biological processes. Whether or not mammalian cells will grow and divide is determined by a variety of feedback control mechanisms, which include the availability of space in which a cell can grow and the secretion of specific stimulatory and inhibitory factors in the immediate environment.

- 2 -

When normal cellular proliferation is disturbed or somehow disrupted, the results can be inconsequential or they can be the manifestation of an array of biological disorders. Disruption of proliferation could be due to a myriad of factors such as the absence or overabundance of various signaling chemicals or presence of altered environments. Some disorders characterized by abnormal cellular proliferation include cancer, abnormal development of embryos, improper formation of the corpus luteum, difficulty in wound healing as well as malfunctioning of inflammatory and immune responses.

Cancer is characterized by abnormal cellular proliferation. Cancer cells exhibit a number of properties that make them dangerous to the host, often including an ability to invade other tissues and to induce capillary ingrowth, which assures that the proliferating cancer cells have an adequate supply of blood. One of the defining features of cancer cells is that they respond abnormally to control mechanisms that regulate the division of normal cells and continue to divide in a relatively uncontrolled fashion until they kill the host.

Angiogenesis and angiogenesis related diseases are closely affected by cellular proliferation. As used herein, the term "angiogenesis" means the generation of new blood vessels into a tissue or organ. Under normal physiological conditions, humans or animals undergo angiogenesis only in very specific restricted situations. For example, angiogenesis is normally observed in wound healing, fetal and embryonal development and formation of the corpus luteum, endometrium and placenta. The term "endothelium" is defined herein as a thin layer of flat cells that lines serous cavities, lymph vessels, and blood vessels. These cells are defined herein as "endothelial cells". The term "endothelial inhibiting activity" means the capability of a molecule to inhibit angiogenesis in general. The inhibition of endothelial cell proliferation also results in an inhibition of angiogenesis.

- 3 -

Both controlled and uncontrolled angiogenesis are thought to proceed in a similar manner. Endothelial cells and pericytes, surrounded by a basement membrane, form capillary blood vessels. Angiogenesis begins with the erosion of the basement membrane by enzymes released by endothelial cells and leukocytes. The endothelial cells, which line the lumen of blood vessels, then protrude through the basement membrane. Angiogenic stimulants induce the endothelial cells to migrate through the eroded basement membrane. The migrating cells form a "sprout" off the parent blood vessel, where the endothelial cells undergo mitosis and proliferate. The endothelial sprouts merge with each other to form capillary loops, creating the new blood vessel.

Persistent, unregulated angiogenesis occurs in a multiplicity of disease states, tumor metastasis and abnormal growth by endothelial cells and supports the pathological damage seen in these conditions. The diverse pathological disease states in which unregulated angiogenesis is present have been grouped together as angiogenic-dependent, angiogenic-associated, or angiogenic-related diseases. These diseases are therefore a result of abnormal or undesirable cell proliferation, particularly endothelial cell proliferation.

The hypothesis that tumor growth is angiogenesis-dependent was first proposed in 1971 by Judah Folkman (*N. Engl. Jour. Med.* 285:1182-1186, 1971). In its simplest terms the hypothesis proposes that once tumor "take" has occurred, every increase in tumor cell population must be preceded by an increase in new capillaries converging on the tumor. Tumor "take" is currently understood to indicate a prevascular phase of tumor growth in which a population of tumor cells occupying a few cubic millimeters volume and not exceeding a few million cells, survives on existing host microvessels. Expansion of tumor volume beyond this phase requires the induction of new capillary blood vessels. For example, pulmonary micrometastases in the early prevascular phase in

- 4 -

mice would be undetectable except by high power microscopy on histological sections.

Further indirect evidence supporting the concept that tumor growth is angiogenesis dependent is found in U.S. Patent Application Serial No. 08/429,743 which is incorporated herein by reference.

Thus, it is clear that cellular proliferation, particularly endothelial cell proliferation, and most particularly angiogenesis, plays a major role in the metastasis of a cancer. If this abnormal or undesirable proliferation activity could be repressed, inhibited, or eliminated, then the tumor, although present, would not grow. In the disease state, prevention of abnormal or undesirable cellular proliferation and angiogenesis could avert the damage caused by the invasion of the new microvascular system. Therapies directed at control of the cellular proliferative processes could lead to the abrogation or mitigation of these diseases.

What is needed therefore is a composition and method which can inhibit abnormal or undesirable cellular proliferation, especially the growth of blood vessels into tumors. The composition should be able to overcome the activity of endogenous growth factors in premetastatic tumors and prevent the formation of the capillaries in the tumors thereby inhibiting the development of disease and the growth of tumors. The composition should also be able to modulate the formation of capillaries in angiogenic processes, such as wound healing and reproduction. Finally, the composition and method for inhibiting cellular proliferation should preferably be non-toxic and produce few side effects.

30

#### SUMMARY OF THE INVENTION

In accordance with the present invention, compositions and methods are provided that are effective in inhibiting abnormal or undesirable cell proliferation, especially endothelial cell proliferation and angiogenesis

35

- 5 -

related to tumor growth. The composition provided herein contains a protein known as "tissue factor pathway inhibitor" (TFPI), a TFPI homolog, or an active fragment thereof, wherein the fragment is defined by its ability to exhibit antiproliferative activity on human and other animal endothelial cells. Tissue factor pathway inhibitor is a protein having a molecular weight of between approximately 32 kilodaltons and 45 kilodaltons and having a structure of approximately 276 amino acids consisting of an acidic amino terminus followed by three Kunitz-type protease inhibitor domains and a basic carboxyl terminal region.

The methods provided herein for treating diseases and processes mediated by undesired and uncontrolled cell proliferation, such as cancer, involve administering to a human or animal a composition containing a substantially purified tissue factor pathway inhibitor (TFPI), TFPI homolog, or active fragment thereof, in a dosage sufficient to inhibit cell proliferation, particularly endothelial cell proliferation. The method is especially useful for treating or repressing the growth of tumors, particularly by inhibiting angiogenesis. Administration of the composition to a human or animal having prevascularized metastasized tumors is useful for preventing the growth or expansion of those tumors.

Accordingly, it is an object of the present invention to provide a method of treating diseases and processes that are mediated by abnormal or undesirable cellular proliferation.

It is another object of the present invention to provide a composition for treating or repressing the growth of a cancer.

It is yet another object of the present invention to provide a therapy for cancer that has minimal side effects.

It is another object of the present invention to provide a method and composition for treating diseases and processes that are mediated by angiogenesis.

- 6 -

These and other objects, features and advantages of the present invention will become apparent after a review of the following detailed description of the disclosed embodiments and the appended claims.

5

#### BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a schematic diagram of tissue factor pathway inhibitor (TFPI) showing its structure, including the three Kunitz domains.

10

Figure 2 is a diagram of the blood coagulation cascade.

15

Figures 3a-3d are graphs depicting the results of proliferation assays testing various forms of TFPI using uridine incorporation: Figure 3a is a graph showing the antiproliferative activity of full length TFPI purified from human plasma. Figure 3b is a graph showing the antiproliferative activity of TFPI purified from HepG2 cells. Figure 3c is a graph showing the antiproliferative activity of full length recombinant TFPI. Figure 3d is a graph showing the antiproliferative activity of recombinant TFPI using cell counting.

20

Figure 4 is a graph comparing the antiproliferative activity of TFPI purified from human plasma and TFPI purified HepG2 cells in a HUVE cell proliferation assay.

25

Figures 5a and 5b are graphs showing cell proliferation activity after administration of TFPI and Heparin. In Figure 5a, equimolar concentrations of TFPI and heparin were used. In Figure 5b, the concentration of heparin was 5-fold in excess of the concentration of TFPI.

30

Figure 6 is a graph depicting the effect of recombinant TFPI containing only the first two Kunitz domains on proliferation of HUVE cells.



- 7 -

Figure 7 is a schematic diagram of tissue factor pathway inhibitor-2 (TFPI-2) showing its structure, including the three Kunitz domains.

5           **DETAILED DESCRIPTION**

          Compositions and methods for the treatment of diseases and processes that are mediated by or associated with abnormal or undesirable cellular proliferation are provided. The composition contains tissue factor pathway inhibitor (TFPI). TFPI is defined herein as including TFPI homologs such as TFPI-2. TFPI is also defined herein as including active fragments of the tissue factor pathway inhibitor molecule. Active fragments of TFPI are defined herein as fragments having the ability to exhibit anti-proliferative activity on human and other animal endothelial cells by *in vivo* or *in vitro* assays or other known techniques. Active fragments of TFPI are further defined herein as fragments having an inhibitory or repressive effect on angiogenesis. TFPI is further defined as including proteins or active fragments thereof belonging to a family, or superfamily, of proteins that contain Kunitz-type protease inhibitor (KPI) domains, such as amyloid beta precursor protein and other serine protease inhibitors.

          In accordance with the method, TFPI is administered to a human or animal exhibited undesirable cell proliferation in an amount sufficient to inhibit the undesirable cell proliferation, particularly endothelial cell proliferation, angiogenesis or an angiogenesis-related disease.

TFPI Characteristics

          TFPI, as defined herein, is a glycoprotein having a molecular weight of approximately 32 to 45 kilodaltons. TFPI is composed of approximately 276 amino acids organized in a structure that includes an acidic amino terminus followed by three Kunitz-type protease inhibitor domains, referred to as Kunitz-1, Kunitz-2, and Kunitz-3, and a basic carboxyl

- 8 -

terminal region as shown in Fig. 1. TFPI has a total of three glycosylation sites, located at amino acids 117, 167, and 228.

5 TFPI, also known to those skilled in the art as lipoprotein-associated coagulation inhibitor, is a protease inhibitor that plays an important role in the regulation of tissue factor-induced blood coagulation. TFPI functions primarily by interfering with the function of certain components in the blood coagulation system, more specifically by binding and inactivating factor X and binding to and inhibiting Tissue Factor/VIIa.

10 Blood coagulation is complex series of interactions and is usually described as a cascade type reaction wherein a sequence of reactions involves numerous enzymes and cofactors. Coagulation consists of both an intrinsic and extrinsic pathway, the end result of which is the conversion of fibrinogen to fibrin. The blood coagulation cascade is shown in Fig. 2.

20 The extrinsic system occurs in parallel with the intrinsic system and may be defined as coagulation initiated by components present entirely within the vascular system. Trauma to endothelial cells causes the conversion of Factor VII to Factor VII<sub>a</sub> which, in the presence of Tissue Factor (TF), activates Factor X converting it to Factor X<sub>a</sub>. Once Factor X<sub>a</sub> is formed it converts prothrombin to thrombin, which finally facilitates the conversion of fibrinogen to fibrin in the presence of thrombin, and from fibrin to a cross-linked fibrin clot.

30 In the blood coagulation cascade, TFPI blocks the initial steps of the extrinsic pathway by binding and inactivating factor X<sub>a</sub> and by binding and inhibiting tissue factor/factor VII<sub>a</sub> complex. The Kunitz-1 domain of TFPI is responsible for the inhibition of factor VII<sub>a</sub> of the tissue factor/factor VII<sub>a</sub> complex while the Kunitz-2 domain is responsible for the inhibition of factor X<sub>a</sub>. The role of Kunitz-3 is not yet understood, although a heparin-binding site

35

- 9 -

has been localized in its basic region. The main heparin-binding site of TFPI is located in the carboxyl terminus of the molecule.

#### TFPI Localization and Production

5                   Generally, TFPI is found in plasma, in platelets  
and on endothelium. Its plasma concentration is low  
(approximately 3nM), and the majority of circulating TFPI is  
bound to lipoproteins (LDL, HDL, and lipoprotein (a)).  
10                  Platelets carry approximately 10% of the total TFPI  
concentration, and they release it after acute stimulation. At a  
site of blood vessel injury and after the bleeding has stopped,  
there is a three-fold increase in the concentration of TFPI  
compared to the normal levels found in plasma. This  
15                  additional TFPI is derived by the aggregated platelets at the  
site of the injury. The majority of intravascular TFPI is  
endothelium-bound and is released after heparin infusion. The  
amount of the heparin-releasable TFPI is believed to be two to  
ten times the amount found in plasma or 220-800 ng/ml.

                  Intravascular TFPI exists in several forms. The  
20                  predominant forms of plasma TFPI have molecular weights of  
34 and 41 KDa but other forms with higher molecular weights  
are also present. The form of TFPI that circulates while  
bound to LDL has a molecular mass of 34 KDa and lacks the  
carboxyl-terminal region and part of the Kunitz-3 domain.  
25                  The 41 KDa form of TFPI circulates while bound to HDL and  
is truncated like one of the 34 KDa forms. This form of TFPI  
has a higher molecular weight because it is linked via a  
disulfide bond to apolipoprotein A-II. The heparin-releasable  
TFPI is not truncated and is fully glycosylated.

30                  TFPI is synthesized in endothelial cells and is  
exocytosed toward the surface of the cells where it remains  
bound to heparin sulfate proteoglycans (HSPGs). The liver is  
mainly responsible for the clearance of circulating TFPI. In  
the liver, the low density lipoprotein receptor-related protein  
35                  (LRP) mediates the uptake and degradation of TFPI by

- 10 -

hepatoma cells. This LRP-mediated clearance of TFPI involves two steps. Initially TFPI binds to HSPGs on the surface of the cells and is then transferred to LRP for internalization.

5 TFPI is isolated from body fluids including, but not limited to, serum, urine, and ascites, or synthesized by chemical or biological methods, such as cell culture, recombinant gene expression, and peptide synthesis. Recombinant techniques include gene amplification from DNA  
10 sources using the polymerase chain reaction (PCR), and gene amplification from RNA sources using reverse transcriptase/PCR. The amino acid sequence of TFPI is known and is set forth schematically in Fig. 1 and in SEQ ID No. 1. By definition, fragments of TFPI have an amino acid sequence  
15 within the amino acid sequence set forth in SEQ ID No. 1. TFPI is extracted from body fluids by known protein extraction methods, particularly the method described by Novotny, W.F., *et al.*, "Purification and Characterization of the Lipoprotein-Associated Coagulation Inhibitor From Human Plasma", *J. Biol. Chem.* 1989; 264: 18832-18837.  
20

TFPI-2 is a homolog of TFPI and has a molecular mass of 32 kDa.. The amino acid sequence of TFPI is known and is set forth schematically in Fig. 7 and in SEQ ID No. 2. By definition, fragments of TFPI-2 have an amino acid  
25 sequence within the amino acid sequence set forth in SEQ ID No. 2. Characteristics of TFPI-2 are described in the scientific article of Sprecher, Cindy A., *et al.*, *Proc. Natl. Acad. Sci., USA*, 91:3353-3357 (1994), which is incorporated by reference herein. TFPI-2 is also known by those skilled in the  
30 art as placental protein 5 as described in the scientific article of Miyagi, Y., *et al.*, *J. Biochem.* 116:939-942 (1994), which is incorporated by reference herein. Additional properties of TFPI-2 are described in the scientific article of Petersen, L.C., *et al.*, *Biochem.* 35:266-272 (1996), which is incorporated by  
35 reference herein.

- 11 -

TFPI Fragments

TFPI fragments can be produced and tested for antiproliferative activity using techniques and methods known to those skilled in the art. For example, full length recombinant TFPI (rTFPI) can be produced using the Baculovirus system. The full length TFPI can be cleaved into individual domains or digested using various methods such as, for example, the method described by Enjyoji *et al.* (*Biochemistry* 34:5725-5735 (1995)). In accordance with the method of Enjyoji *et al.*, rTFPI is treated with human neutrophil elastase, and the digest purified using a heparin column. Human neutrophil elastase cleaves TFPI at Leu<sup>89</sup> into two fragments: one containing Kunitz-1 and the other containing Kunitz-2 and Kunitz-3. The fragment containing Kunitz-2 and Kunitz-3 (Kunitz-2/Kunitz-3) is further treated with hydroxylamine according to the method of Balian *et al.* (*Biochemistry* 11:3798-3806 (1972)), and the digest purified using a heparin column. Hydroxylamine cleaves the fragment containing Kunitz-2 and Kunitz-3 into two fragments: one containing Kunitz-3 and the other containing the Kunitz-2 domain. The fragments containing the Kunitz-1 domain, Kunitz-2 domain, Kunitz-3 domain, and Kunitz-2/Kunitz-3 domain are then tested for the ability to inhibit bFGF-induced cell proliferation, particularly endothelial cell proliferation as described in the Examples below. As described in the Examples, fragments containing the Kunitz-3 domain have been shown to have anti-proliferative activity.

Alternatively, fragments are prepared by digesting the entire TFPI molecule, or large fragments thereof exhibiting anti-proliferative activity, to remove one amino acid at a time. Each progressively shorter fragment is then tested for anti-proliferative activity. Similarly, TFPI fragments of various lengths may be synthesized and tested for anti-proliferative activity. By increasing or decreasing the length of a fragment, one skilled in the art may determine the exact

- 12 -

number, identity, and sequence of amino acids within the TFPI molecule that are required for anti-proliferative activity using routine digestion, synthesis, and screening procedures known to those skilled in the art.

5           Anti-proliferative activity is evaluated *in situ* by testing the ability of TFPI fragments to inhibit the proliferation of new blood vessel cells, referred to herein as the inhibition of angiogenesis. A suitable assay is the chick embryo chorioallantoic membrane (CAM) assay described by  
10           Crum *et al.*, *Science* 230:1375 (1985) and described in U.S. Patent No. 5,001,116, which is incorporated by reference herein. The CAM assay is briefly described as follows. Fertilized chick embryos are removed from their shell on day 3 or 4, and a methylcellulose disc containing the TFPI  
15           fragment composition is implanted on the chorioallantoic membrane. The embryos are examined 48 hours later and, if a clear avascular zone appears around the methylcellulose disc, the diameter of that zone is measured. The larger the diameter of the zone, the greater the anti-angiogenic activity.

20           TFPI Compositions

          A composition containing TFPI, a TFPI homolog, or an active fragment of TFPI or a TFPI homolog, can be prepared in a physiologically acceptable formulation, such as  
25           in a pharmaceutically acceptable carrier, using known techniques. For example, TFPI, a TFPI homolog, or an active fragment thereof is combined with a pharmaceutically acceptable excipient to form a therapeutic composition.

          Alternatively, the gene for TFPI or peptide fragments thereof may be delivered in a vector for continuous  
30           TFPI administration using gene therapy techniques. The vector may be administered in a vehicle having specificity for a target site, such as a tumor.

          The therapeutic composition may be in the form of a solid, liquid or aerosol. Examples of solid compositions  
35           include pills, creams, and implantable dosage units. Pills may

- 13 -

5 be administered orally. Therapeutic creams may be administered topically. Implantable dosage units may be administered locally, for example, at a tumor site, or may be implanted for systematic release of the therapeutic  
10 angiogenesis-modulating composition, for example, subcutaneously. Examples of liquid compositions include formulations adapted for injection subcutaneously, intravenously, intra-arterially, and formulations for topical and intraocular administration. Examples of aerosol  
15 formulations include inhaler formulations for administration to the lungs.

The composition may be administered by standard routes of administration. In general, the composition may be administered by topical, oral, rectal, nasal or parenteral (for  
20 example, intravenous, subcutaneous, or intermuscular) routes. In addition, the composition may be incorporated into sustained release matrices such as biodegradable polymers, the polymers being implanted in the vicinity of where delivery is desired, for example, at the site of a tumor. The method  
25 includes administration of a single dose, administration of repeated doses at predetermined time intervals, and sustained administration for a predetermined period of time.

A sustained release matrix, as used herein, is a matrix made of materials, usually polymers which are  
30 degradable by enzymatic or acid/base hydrolysis or by dissolution. Once inserted into the body, the matrix is acted upon by enzymes and body fluids. The sustained release matrix desirably is chosen by biocompatible materials such as liposomes, polylactides (polylactide acid), polyglycolide (polymer of glycolic acid), polylactide co-glycolide (copolymers of lactic acid and glycolic acid), polyanhydrides, poly(ortho)esters, polypeptides, hyaluronic acid, collagen, chondroitin sulfate, carboxylic acids, fatty acids, phospholipids, polysaccharides, nucleic acids, polyamino acids,  
35 amino acids such phenylalanine, tyrosine, isoleucine,

- 14 -

polynucleotides, polyvinyl propylene, polyvinylpyrrolidone and silicone. A preferred biodegradable matrix is a matrix of one of either of polylactide, polyglycolide, or polylactide co-glycolide (co-polymers of lactic acid and glycolic acid).

5           The dosage of the composition will depend on the condition being treated, the particular composition used, and other clinical factors such as weight and condition of the patient, and the route of administration.

10           The composition may be administered in combination with other compositions and procedures for the treatment of diseases. For example, unwanted cell proliferation may be treated conventionally with surgery, radiation or chemotherapy in combination with the administration of TFPI, TFPI homologs, or active fragments thereof, and additional doses of TFPI, TFPI homologs, or  
15           active fragments thereof may be subsequently administered to the patient to stabilize and inhibit the growth of any residual unwanted cell proliferation.

20           The methods and compositions are useful for treating diseases and processes that are mediated by abnormal or undesirable cellular proliferation, particularly abnormal or undesirable endothelial cell proliferation, including, but not limited to, hemangioma, solid tumors, leukemia, metastasis, telangiectasia psoriasis scleroderma, pyogenic  
25           granuloma, myocardial angiogenesis, plaque neovascularization, coronary collaterals, ischemic limb angiogenesis, corneal diseases, rubeosis, neovascular glaucoma, diabetic retinopathy, retrolental fibroplasia, arthritis, diabetic neovascularization, macular degeneration, wound healing,  
30           peptic ulcer, fractures, keloids, vasculogenesis, hematopoiesis, ovulation, menstruation, and placentation. The method and composition are particularly useful for treating angiogenesis-related disorders and diseases by inhibiting angiogenesis. As described in more detail below, recombinant, full length TFPI  
35           is approximately ten times more potent for inhibiting



- 15 -

angiogenesis than other known endogenous inhibitors of angiogenesis such as recombinant PF-4, and Kringle 1-3 of the Angiostatin<sup>TM</sup> molecule.

5 The methods and compositions described herein are particularly useful for treating cancer, arthritis, macular degeneration, and diabetic retinopathy

10 This invention is further illustrated by the following non-limiting examples, which are not to be construed in any way as imposing limitations upon the scope thereof. On the contrary, it is to be clearly understood that resort may be had to various other embodiments, modifications, and equivalents thereof which, after reading the description herein, may suggest themselves to those skilled in the art without departing from the spirit of the present invention and/or the scope of the appended claims.

### Example 1

#### 20 *Effect of TFPI on bFGF-induced Proliferation of Human Endothelial Cells*

25 Proliferation assays familiar to those skilled in the art using human umbilical vein endothelial (HUVE) cells were used to determine the effect of TFPI on bFGF-induced proliferation of human umbilical vein endothelial cells.

TFPI from the following sources was tested:

1. full length, fully glycosylated TFPI (molecular weight 43,000) purified from human plasma
2. TFPI purified from HepG2 cells containing full length and carboxyl-terminal lacking molecules
- 30 3. full length, partially glycosylated TFPI (molecular weight 35,000) produced recombinantly
4. truncated, partially glycosylated (molecular weight 21,000) produced recombinantly

35

- 16 -

### *Materials and Methods*

The materials for this experiment included HUVE cells and media for their proliferation, Endothelial Cell Basal Medium (EBM) and Endothelial Cell Growth Medium (EGM), (Clonetics, San Diego, CA). Also used was TFPI purified from human plasma or HepG2 cells, recombinant full length TFPI, and recombinant truncated TFPI (1-160 amino acids) (all from American Diagnostica Inc., Greenwich, CT). In addition, a cell proliferation ELISA BrdU (Boehringer Mannheim Corporation, Indianapolis, IN), bFGF (R&D, Minneapolis, MN) and heparin (Sigma Chemical Company, St. Louis, MO) were used.

The proliferation assay involved the routine culturing of human umbilical vein endothelial (HUVE) cells to confluency in EGM media. The cells were trypsinized and plated in a 96-well plate at 5000 cells per well per 100 $\mu$ L EBM media. The cells were allowed to adhere to the plate for at least 2 hours. Next, bFGF at 10 ng/ml and TFPI at various concentrations were added to the wells. The cells were cultured for 48 hours after which cell proliferation was determined using a standard uridine incorporation method.

### *Results*

As indicated below, TFPI from all three sources inhibited bFGF-induced proliferation of human umbilical vein endothelial cells. The relative proliferative effects of TFPI are shown graphically in Figures 3a - 3d. TFPI purified from human plasma and HepG2 cells had comparable activities indicating that neither glycosylation nor heparin binding was responsible for the antiproliferative activity of TFPI. (Figure 4).

- 17 -

Source of TFPI	Effect on Proliferation
Purified From Human Plasma	Inhibition of Proliferation
Purified From HepG2 cells	Inhibition of Proliferation
Recombinant, Full Length (1-216 amino acids)	Inhibition of Proliferation
Recombinant, truncated (1-160 amino acids)	No Inhibition of Proliferation

### Example 2

#### *Effect of Heparin on TFPI Inhibition of bFGF-induced Proliferation*

Proliferation assays using HUVE cells, as described in Example 1, were used to determine the effect of heparin on TFPI inhibition of bFGF-induced proliferation. The purpose of this study was to determine whether heparin was able to neutralize the antiproliferative activity of TFPI.

TFPI was pre-incubated with equimolar concentrations of heparin and with concentrations of heparin that were five-fold in excess of the concentration of TFPI. The results are summarized below and are presented graphically in Figs. 5a and 5b.

Relative Concentration of Heparin & TFPI	Antiproliferative Activity of TFPI
Equimolar Heparin and TFPI	No Effect
Heparin 5-fold excess > TFPI	No Effect

When TFPI was pre-incubated with equimolar and five-fold in excess concentrations of heparin, it did not lose its antiproliferative activity. Together these data demonstrate that TFPI does not inhibit bFGF induced proliferation of endothelial cells by binding to HSPGs on the surface of the cells and thus obstructing the binding of bFGF to heparin sulfates.

- 18 -

### Example 3

#### 5      *Comparison of the Effects of Native and Recombinant TFPI on bFGF-induced Proliferation of Endothelial Cells*

Cell proliferation assays, as described in Example 1, were conducted to determine the relative potency of native TFPI versus recombinant TFPI.

#### 10      Results

Fifty percent inhibition of the bFGF-induced proliferation of HUVE cells was obtained with 75 nM for the full length, fully glycosylated native TFPI and with 150 nM for the full length, recombinant TFPI. Therefore, there is a  
15      significant difference in the ability to inhibit proliferation by native and recombinant TFPI, with native TFPI being decidedly more potent.

### Example 4

#### 20      *Comparison of the Inhibitory Activity of Recombinant TFPI to Other Endogenous Angiogenesis Inhibitors*

Cell proliferation assays, as described in Example 1, were conducted using full length recombinant TFPI, Platelet Factor 4 (PF-4), and recombinant Kringle 1-3 of Angiostatin™ peptide. Both PF-4 and Angiostatin™ peptide are known endogenous inhibitors of angiogenesis. PF-4 is a protein involved in the blood coagulation cascade and is referenced as  
25      an inhibitor of angiogenesis by Maione, T. *et al.* in the article "Inhibition of Angiogenesis by Recombinant Human Platelet Factor-4 and Related Peptides" *Science* 247:77 (1990). Angiostatin is a fragment of plasminogen and its inhibitory effect on angiogenesis is described by Cao, Y. *et al.* in the  
30      article "Kringle Domains of Human Angiostatin" *J. Biol. Chem.* 271:1 (1996).  
35

- 19 -

PF-4 and TFPI were tested for inhibition of human umbilical vein endothelial cell (HUVEC) proliferation. Angiostatin™ peptide was tested for the inhibition of bovine capillary endothelial (BCE) proliferation. The results are summarized below.

### Results

Angiogenesis Inhibitor	Concentration for 50% Inhibition
Recombinant TFPI	Approx. 0.125μm
PF-4	1.25μm
Kringle 1-3 Angiostatin™	0.190μm

Full length recombinant TFPI is approximately ten times more potent than recombinant PF-4, which requires 1.25 μM for 50% inhibition of HUVE cell proliferation. Full length recombinant TFPI is also more active than recombinant Kringle 1-3 of angiostatin, which requires approximately 0.190 μM for 50% inhibition of BCE proliferation.

### Example 5

#### *Localization of Relevant Domains of Recombinant TFPI for Inhibitory Activity on Proliferation of Endothelial Cells*

Cell proliferation assays, as described above in Example 1, were conducted using fragments of recombinant TFPI containing the following domains: Kunitz-1, Kunitz-2, or Kunitz-3.

### Results

Recombinant TFPI containing only Kunitz-1, and Kunitz-2 (1-160 amino acids) did not result in the inhibition of proliferation of endothelial cells. However, recombinant TFPI containing Kunitz-3 did result in the inhibition of proliferation as shown in Fig. 6. These results indicate that Kunitz-3 or an active portion thereof most probably plays an important role

- 20 -

affecting the activity of TFPI or the binding of TFPI to its receptor on the surface of the endothelial cells.

## SEQUENCE LISTING

- 5 (1) GENERAL INFORMATION:
- (i) APPLICANT: Papathanassiu, Adonia E  
Green, Shawn J.
- 10 (ii) TITLE OF INVENTION: Compositions and Methods for  
Inhibiting Cellular Proliferation
- (iii) NUMBER OF SEQUENCES: 2
- 15 (iv) CORRESPONDENCE ADDRESS:  
(A) ADDRESSEE: Jones & Askew  
(B) STREET: 191 Peachtree Street, 37th Floor  
(C) CITY: Atlanta  
(D) STATE: Georgia  
20 (E) COUNTRY: U.S.A.  
(F) ZIP: 30303
- (v) COMPUTER READABLE FORM:  
(A) MEDIUM TYPE: Floppy disk  
25 (B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:  
30 (A) APPLICATION NUMBER: US  
(B) FILING DATE:  
(C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:  
35 (A) NAME: Greene, Jamie L.  
(B) REGISTRATION NUMBER: 32,467  
(C) REFERENCE/DOCKET NUMBER: 05213-0290
- (ix) TELECOMMUNICATION INFORMATION:  
40 (A) TELEPHONE: (404) 818-3700  
(B) TELEFAX: (404) 818-3799

## (2) INFORMATION FOR SEQ ID NO:1:

- 5           (i) SEQUENCE CHARACTERISTICS:  
            (A) LENGTH: 276 amino acids  
            (B) TYPE: amino acid  
            (C) STRANDEDNESS: single  
            (D) TOPOLOGY: linear
- 10          (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- 15          (v) FRAGMENT TYPE: N-terminal
- (vi) ORIGINAL SOURCE:  
                (A) ORGANISM: Homo sapiens
- 20          (ix) FEATURE:  
                (A) NAME/KEY: Active-site  
                (B) LOCATION: 2..3  
                (D) OTHER INFORMATION: /note= "Site of partial  
25 phosphorylation"
- (ix) FEATURE:  
                (A) NAME/KEY: Active-site  
                (B) LOCATION: 117..118  
30             (D) OTHER INFORMATION: /note= "Potential site for N-linked  
glycosylation"
- (ix) FEATURE:  
                (A) NAME/KEY: Active-site  
35             (B) LOCATION: 167..168  
                (D) OTHER INFORMATION: /note= "Potential site for N-linked  
glycosylation"
- (ix) FEATURE:  
40             (A) NAME/KEY: Active-site  
                (B) LOCATION: 228..229  
                (D) OTHER INFORMATION: /note= "Potential site for N-linked  
glycosylation"
- 45          (ix) FEATURE:  
                (A) NAME/KEY: Domain  
                (B) LOCATION: 26..76  
                (D) OTHER INFORMATION: /label= Kunitz-1



23

## (ix) FEATURE:

(A) NAME/KEY: Domain  
 (B) LOCATION: 97..147  
 (D) OTHER INFORMATION: /label= Kunitz-2

5

## (ix) FEATURE:

(A) NAME/KEY: Domain  
 (B) LOCATION: 189..239  
 (D) OTHER INFORMATION: /label= Kunitz-3

10

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

15

Asp Ser Glu Glu Asp Glu Glu His Thr Ile Ile Thr Asp Thr Glu Leu  
 1 5 10 15

Pro Pro Leu Lys Leu Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp  
 20 25 30

20

Gly Pro Cys Lys Ala Ile Met Lys Arg Phe Phe Phe Asn Ile Phe Thr  
 35 40 45

25

Arg Gln Cys Glu Glu Phe Ile Tyr Gly Gly Cys Glu Gly Asn Gln Asn  
 50 55 60

Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp Asn  
 65 70 75 80

30

Ala Asn Arg Ile Ile Lys Thr Thr Leu Gln Gln Glu Lys Pro Asp Phe  
 85 90 95

Cys Phe Leu Glu Glu Asp Pro Gly Ile Cys Arg Gly Tyr Ile Thr Arg  
 100 105 110

35

Tyr Phe Tyr Asn Asn Gln Thr Lys Gln Cys Glu Arg Phe Lys Tyr Gly  
 115 120 125

40

Gly Cys Leu Gly Asn Met Asn Asn Phe Glu Thr Leu Glu Glu Cys Lys  
 130 135 140

Asn Ile Cys Glu Asp Gly Pro Asn Gly Phe Gln Val Asp Asn Tyr Gly  
 145 150 155 160

45

Thr Gln Leu Asn Ala Val Asn Asn Ser Leu Thr Pro Gln Ser Thr Lys  
 165 170 175

Val Pro Ser Leu Phe Glu Phe His Gly Pro Ser Trp Cys Leu Thr Pro  
 180 185 190

24

Ala Asp Arg Gly Leu Cys Arg Ala Asn Glu Asn Arg Phe Tyr Tyr Asn  
195 200 205

5 Ser Val Ile Gly Lys Cys Arg Pro Phe Lys Tyr Ser Gly Cys Gly Gly  
210 215 220

Asn Glu Asn Asn Phe Thr Ser Lys Gln Glu Cys Leu Arg Ala Cys Lys  
225 230 235 240

10 Lys Gly Phe Ile Gln Arg Ile Ser Lys Gly Gly Leu Ile Lys Thr Lys  
245 250 255

Arg Lys Arg Lys Lys Gln Arg Val Lys Ile Ala Tyr Glu Glu Ile Phe  
15 260 265 270

Val Lys Asn Met  
275

20

25

## (2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:  
30 (A) LENGTH: 213 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein  
35
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- 40 (v) FRAGMENT TYPE: N-terminal
- (vi) ORIGINAL SOURCE:  
(A) ORGANISM: Homo sapiens

45

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

5	Asp	Ala	Ala	Gln	Glu	Pro	Thr	Gly	Asn	Asn	Ala	Glu	Ile	Cys	Leu	Leu	1	5	10	15
	Pro	Leu	Asp	Tyr	Gly	Pro	Cys	Arg	Ala	Leu	Leu	Leu	Arg	Tyr	Tyr	Tyr	20	25	30	
10	Asp	Arg	Tyr	Thr	Gln	Ser	Cys	Arg	Gln	Phe	Leu	Tyr	Gly	Gly	Cys	Glu	35	40	45	
	Gly	Asn	Ala	Asn	Asn	Phe	Tyr	Thr	Trp	Glu	Ala	Cys	Asp	Asp	Ala	Cys	50	55	60	
15	Trp	Arg	Ile	Glu	Lys	Val	Pro	Lys	Val	Cys	Arg	Leu	Gln	Val	Ser	Val	65	70	75	80
20	Asp	Asp	Gln	Cys	Glu	Gly	Ser	Thr	Glu	Lys	Tyr	Phe	Phe	Asn	Leu	Ser	85	90	95	
	Ser	Met	Thr	Cys	Glu	Lys	Phe	Phe	Ser	Gly	Gly	Cys	His	Arg	Asn	Arg	100	105	110	
25	Ile	Glu	Asn	Arg	Phe	Pro	Asp	Glu	Ala	Thr	Cys	Met	Gly	Phe	Cys	Ala	115	120	125	
	Pro	Lys	Lys	Ile	Pro	Ser	Phe	Cys	Tyr	Ser	Pro	Lys	Asp	Glu	Gly	Leu	130	135	140	
30	Cys	Ser	Ala	Asn	Val	Thr	Arg	Tyr	Tyr	Phe	Asn	Pro	Arg	Tyr	Arg	Thr	145	150	155	160
35	Cys	Asp	Ala	Phe	Thr	Tyr	Thr	Gly	Cys	Gly	Gly	Asn	Asp	Asn	Asn	Phe	165	170	175	
	Val	Ser	Arg	Glu	Asp	Cys	Lys	Arg	Ala	Cys	Ala	Lys	Ala	Leu	Lys	Lys	180	185	190	
40	Lys	Lys	Lys	Met	Pro	Lys	Leu	Arg	Phe	Ala	Ser	Arg	Ile	Arg	Lys	Ile	195	200	205	
45	Arg	Lys	Lys	Gln	Phe												210			

- 26 -

## CLAIMS

We claim:

- 5                   1. A method of treating a human or animal having undesirable cell proliferation comprising, administering to the human or animal a sufficient amount of a composition comprising tissue factor pathway inhibitor to inhibit the undesirable cell proliferation.
- 10                   2. The method of Claim 1 wherein the undesirable cell proliferation is undesirable endothelial cell proliferation.
- 15                   3. The method of Claim 1 wherein the undesirable cell proliferation is an angiogenesis-related disease.
- 20                   4. The method of Claim 3, wherein the angiogenic-related disease is a disease selected from the group consisting of cancer, arthritis, macular degeneration, and diabetic retinopathy.
- 25                   5. The method of Claim 1 wherein administration of the composition inhibits angiogenesis.
- 30                   6. The method of Claim 1 wherein the tissue factor pathway inhibitor is a protein or peptide having the amino acid sequence set forth in SEQ ID NO. 1, a homolog thereof, or an anti-proliferative fragment thereof.
- 35                   7. The method of Claim 6 wherein the homolog is a protein or peptide having the amino acid sequence set forth in SEQ ID NO. 2 or an anti-proliferative fragment thereof.

- 27 -

8. The method of Claim 6 wherein the anti-proliferative fragment contains the Kunitz-3 domain or a fragment thereof.

5

9. The method of Claim 7 wherein the anti-proliferative fragment contains the Kunitz-3 domain or a fragment thereof.

10

10. The method of Claim 1 wherein the composition comprises tissue factor pathway inhibitor and a pharmaceutically acceptable excipient, carrier or sustained-release matrix.

15

11. A composition for inhibiting cell proliferation comprising tissue factor pathway inhibitor in a pharmaceutically acceptable carrier.

20

12. The composition of Claim 11, wherein the tissue factor pathway inhibitor comprises an active fragment of tissue factor pathway inhibitor, wherein the active fragment inhibits cell proliferation.

25

13. The composition of Claim 12 wherein the active fragment inhibits endothelial cell proliferation.

14. The composition of Claim 12 wherein the active fragment inhibits angiogenesis.

30

15. The composition of Claim 12 wherein the active fragment inhibits angiogenesis-related disease.

- 28 -

16. The composition of Claim 15, wherein the angiogenic-related disease is a disease selected from the group consisting of cancer, arthritis, macular degeneration, and diabetic retinopathy.

5

17. The composition of Claim 12 wherein the active fragment is a peptide having an amino acid sequence within the amino acid sequence set forth in SEQ ID NO. 1.

10

18. The composition of Claim 12 wherein the active fragment is a peptide having an amino acid sequence within the amino acid sequence set forth in SEQ ID NO. 2.

15

19. The composition of Claim 11 wherein the active fragment contains the Kunitz-3 domain or a fragment thereof.

20

20. The composition of Claim 10, wherein the carrier is a sustained-release matrix.

1/6




Figure 1

Figure 2  
(prior art)

## INTRINSIC PATHWAY

Damaged surface

Kininogen  
Kallikrein

XII

XII<sub>a</sub>

XI

XI<sub>a</sub>

IX

IX<sub>a</sub>VIII<sub>a</sub>

X

X<sub>a</sub>

## EXTRINSIC PATHWAY

Trauma

VII<sub>a</sub>

VII

Tissue factor

Trauma

X

X<sub>a</sub>V<sub>a</sub>Prothrombin  
(II)Thrombin  
(II<sub>a</sub>)Fibrinogen  
(I)Fibrin  
(I<sub>a</sub>)XIII<sub>a</sub>Cross-linked  
fibrin clotFINAL  
COMMON  
PATHWAY

2/6

Figure 3a





Figure 3b





3/6

Figure 3c





Figure 3d



4/6




Figure 4




Figure 6

5/6

Figure 5a






Figure 5b





## Figure 7

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/02699

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 38/00, 38/04; C07K 14/00

US CL : 514/02, 12; 530/324

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/02, 12; 530/324

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, CAS ONLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- Y	US 5,653,744 A (KHOURI et al.) 05 August 1997, columns 5 and 8.	1,6,10 --- 1-10

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* *A* *E* *L* *O* *P*	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance earlier document published on or after the international filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed	*T* *X* *Y* *&*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family
--------------------------------------	---	--------------------------	--

Date of the actual completion of the international search

31 MARCH 1998

Date of mailing of the international search report

03 JUN 1998

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Authorized officer

MICHAEL BORIN



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/02699

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	STEINHUBL, S. R. et al. Local delivery of tissue factor pathway inhibitor (TFPI) to reduce neointimal proliferation in the porcine coronary balloon injury model. Journal Of The American College Of Cardiology. February 1997, Vol. 29, No. 2, Supp. (A), pages 97557-97557, see entire abstract No. 757-57.	1,6,10 --- 1-10
X,P	KAMIKUBO, Y-I et al. A Human recombinant tissue-factor pathway inhibitor prevents the proliferation of cultured human neonatal aortic smooth muscle cells. FEBS Letters. 1997, Vol. 407, pages 116-120, see entire document.	1-10
X --- Y	KHOURI, R. K. et al. Local Application of Tissue Factor Pathway Inhibitor (TFPI) Inhibits Intimal Hyperplasia Induced by Arterial Interventions. Surgical Forum, 1995, Vol. 46, pages 389-391, see entire document.	1,6,10 --- 1-10
A	Database Medline on Dialog, US National Library of Medicine, (Bethesda, MD USA) No. 95041179, DAVIES M.G. et al. 'Pathobiology of intimal hyperplasia'. British Journal Of Surgery. September 1994, Vol. 81, pages 1254-69.	1-10
A	Database Medline on Dialog, US National Library of Medicine, (Bethesda, MD USA) No. 91365975, HAAS A.F. et al. 'Angiolymphoid hyperplasia with eosinophilia of the hand A case report'. Journal Of Dermatologic Surgery And Oncology. September 1991, Vol. 17, pages 731-734.	1-10
A	Database Medline on Dialog, US National Library of Medicine, (Bethesda, MD USA) No. 85118612, CARDIFF R D. 'Protoneoplasia: the molecular biology of murine hyperplasia'. Advances In Cancer Research. 1984, Vol. 42, pages 167-90.	1-10

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/02699

### BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1.

- I. Claims 1-10, drawn to method of treatment comprising administration of TFPI.
- II. Claims 11-20, drawn to composition comprising tissue factor pathway inhibitor.

The inventions listed as Groups I,II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Inventions I and II are related as product and process of use. The product of Group II as claimed can be used in a materially different processes such as treatment of thrombotic conditions, peptide synthesis. Further, inhibition of proliferation or angiogenesis can be practiced with a broad variety of drugs beyond TFPI.

1/6




Figure 1

Figure 2  
(prior art)

## INTRINSIC PATHWAY

Damaged surface

Kininogen

Kallikrein

XII

XII<sub>a</sub>

XI

XI<sub>a</sub>

IX

IX<sub>a</sub>

VIII

VIII<sub>a</sub>

X

X<sub>a</sub>

V

V<sub>a</sub>Prothrombin  
(II)Thrombin  
(II<sub>a</sub>)Fibrinogen  
(I)Fibrin  
(I<sub>a</sub>)

XIII

XIII<sub>a</sub>Cross-linked  
fibrin clot

## EXTRINSIC PATHWAY

Trauma

VII

VII<sub>a</sub>Tissue  
factor

Trauma

FINAL  
COMMON  
PATHWAY



2/6

Figure 3a





Figure 3b



3/6

Figure 3c





Figure 3d



4/6




Figure 4




Figure 6

5/6

Figure 5a





Figure 5b



6/6




Figure 7